Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03986515 | Apatinib Plus SHR1210 in Advanced Mucosal Melanoma | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Jun 14, 2019 | clinicaltrials |
| NCT03966456 | Real World Study of Four PD-1 Agents in China | unknown | — | 500 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | May 29, 2019 | clinicaltrials |
| NCT02909517 |
| The Role of Inflammation in Ocular Tumours |
| unknown |
| — |
| 30 |
| Unity Health TorontoOTHER |
| 1 |
| May 23, 2019 |
| clinicaltrials |
| NCT03955354 | PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma | unknown | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 20, 2019 | clinicaltrials |
| NCT02352428 | Skin Cancer Screening Education Study(SCSES) | unknown | N/A | 113 | Association of Dermatological Prevention, GermanyOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT03917069 | Nab-PCE vs PC for MM After Failure of Anti-PD-1 | unknown | Phase 2 | 145 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT02861209 | Collaborative Network to Take Responsibility for Oral Anticancer Therapy(CONTACT) | unknown | N/A | 228 | KU LeuvenOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03190824 | Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma | unknown | Phase 2 | 4 | Syneos HealthOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03903458 | Tinostamustine and Nivolumab in Advanced Melanoma(ENIgMA) | unknown | Phase 1 | 21 | Markus JoergerOTHER | 1 | Apr 8, 2019 | clinicaltrials |
| NCT03353402 | Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy | unknown | Phase 1 | 40 | Sheba Medical CenterOTHER_GOV | 1 | Apr 3, 2019 | clinicaltrials |
| NCT00849407 | Genetic Risk Factors and Acquired Oncogenic Mutations of Melanoma(M3) | unknown | — | 2,000 | Medical University of ViennaOTHER | 1 | Mar 7, 2019 | clinicaltrials |
| NCT01920516 | Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment(ILI) | unknown | — | 40 | International Group of Endovascular OncologyOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT03454282 | Impact of Dietary Intervention on Tumor Immunity: the DigesT Trial(DIgesT) | unknown | N/A | 100 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT03818893 | Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII | unknown | Phase 2 | 46 | Osaka UniversityOTHER | 1 | Jan 30, 2019 | clinicaltrials |
| NCT03822988 | ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS(PADAONCODERM) | unknown | — | 150 | Central Hospital, Nancy, FranceOTHER | 1 | Jan 30, 2019 | clinicaltrials |
| NCT03797053 | Ex Vivo Expansion of Circulating Tumor Cells as a Model for Cancer Predictive Pharmacology(EXPEVIVO-CTC) | unknown | — | 450 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT03517332 | Circulating Tumor DNA Exposure in Peripheral Blood | unknown | — | 10,000 | Quantgene Inc.INDUSTRY | 2 | Nov 20, 2018 | clinicaltrials |
| NCT02654821 | Study With T-cel Receptor Gene Therapy in Metastatic Melanoma(TCR) | unknown | Phase 1 / Phase 2 | 12 | The Netherlands Cancer InstituteOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT00604136 | Treatment of Metastatic Melanoma With Tumor Infiltrating Lymphocytes and IL-2 Following Lympho-depleting Chemotherapy | unknown | Phase 2 | 20 | Hadassah Medical OrganizationOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT03362138 | Artificial Intelligence-assisted Evaluation of Pigmented Skin Lesions(NNCD) | unknown | — | 80 | Assuta Hospital SystemsOTHER | 1 | Sep 13, 2018 | clinicaltrials |
| NCT03050047 | A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 15 | BiocadINDUSTRY | 1 | Aug 31, 2018 | clinicaltrials |
| NCT03621462 | Elucid Labs AIDA™ - Labelled Image Acquisition Protocol | unknown | N/A | 4,000 | Elucid Labs Inc.INDUSTRY | 1 | Aug 8, 2018 | clinicaltrials |
| NCT01167998 | Early Diagnosis of Malignant Transformation of Pigmentary Skin Lesions | unknown | — | 20 | Hadassah Medical OrganizationOTHER | 1 | Aug 2, 2018 | clinicaltrials |
| NCT03464032 | A Study of BCD-135 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | BiocadINDUSTRY | 1 | Mar 13, 2018 | clinicaltrials |
| NCT03454919 | Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations | unknown | Phase 2 | 60 | Peking University Cancer Hospital & InstituteOTHER | 0 | Mar 6, 2018 | clinicaltrials |
| NCT03449615 | Validation of Ferromagnetic Tracer in Melanoma Sentinel Node(IMINEM) | unknown | — | 186 | Sociedad Española de Oncología QuirúrgicaOTHER | 1 | Mar 1, 2018 | clinicaltrials |
| NCT03435302 | HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma | unknown | Phase 3 | 204 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 19, 2018 | clinicaltrials |
| NCT03422445 | A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma | unknown | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT03138642 | Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Jan 30, 2018 | clinicaltrials |
| NCT03383237 | Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma | unknown | Phase 2 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 27, 2017 | clinicaltrials |
| NCT03098160 | Immunotherapy Study of Evofosfamide in Combination With Ipilimumab | unknown | Phase 1 | 69 | Threshold PharmaceuticalsINDUSTRY | 1 | Oct 30, 2017 | clinicaltrials |
| NCT03048253 | A Phase I-c Study of Recombinant GM-CSF Herpes Simplex Virus to TreatⅣ M1c | unknown | — | 30 | OrienGene Biotechnology Ltd.INDUSTRY | 1 | Oct 2, 2017 | clinicaltrials |
| NCT02625337 | Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients(IMPemBra) | unknown | Phase 2 | 32 | The Netherlands Cancer InstituteOTHER | 1 | Sep 15, 2017 | clinicaltrials |
| NCT02023710 | Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma | unknown | Phase 2 | 182 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT02452294 | Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)(BUMPER) | unknown | Phase 2 | 22 | University Hospital TuebingenOTHER | 1 | May 3, 2017 | clinicaltrials |
| NCT03132090 | Early Therapy Response Monitoring in Melanoma Patients Using PET/MRI | unknown | N/A | 106 | University Hospital TuebingenOTHER | 1 | Apr 27, 2017 | clinicaltrials |
| NCT03095079 | Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma | unknown | Phase 2 | 70 | Peking University Cancer Hospital & InstituteOTHER | 1 | Mar 29, 2017 | clinicaltrials |
| NCT02379000 | TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy | unknown | Phase 4 | 50 | Charite University, Berlin, GermanyOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT02142244 | Fluorescence Surgery for Sentinel Node Identification in Melanoma | unknown | N/A | 318 | Barretos Cancer HospitalOTHER | 1 | Feb 2, 2017 | clinicaltrials |
| NCT03033485 | 18F-Labeled Picolinamide PET Imaging of Melanoma Diagnosis | unknown | N/A | 50 | Xijing HospitalOTHER | 1 | Jan 26, 2017 | clinicaltrials |
| NCT02990416 | A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma | unknown | Phase 1 / Phase 2 | 63 | Virogen Biotechnology Inc.INDUSTRY | 1 | Dec 13, 2016 | clinicaltrials |
| NCT02962947 | MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients | unknown | Phase 2 / Phase 3 | 546 | Azienda Sanitaria di FirenzeOTHER | 0 | Nov 15, 2016 | clinicaltrials |
| NCT02938728 | Definition of an Immune Signature Predictive of Anti-PD1 (Programmed Death-1) Antibody in the Treatment of Advanced Melanoma(PREDIMEL) | unknown | — | 120 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Oct 25, 2016 | clinicaltrials |
| NCT02335476 | Automatic Early Melanoma Detection by Ultrahigh Resolution Three Dimensional Optical Coherence Tomography | unknown | — | 100 | National Taiwan University HospitalOTHER | 1 | Oct 14, 2016 | clinicaltrials |
| NCT01878396 | Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors(CMCBRAF) | unknown | — | 200 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Oct 3, 2016 | clinicaltrials |
| NCT02581228 | Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of Immunotherapy | unknown | — | 500 | Optimata Ltd.INDUSTRY | 1 | Sep 27, 2016 | clinicaltrials |
| NCT02884362 | Prospective Melanoma Database | unknown | — | 10,000 | Institut Claudius RegaudOTHER | 1 | Aug 31, 2016 | clinicaltrials |
| NCT02457650 | T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT02838433 | Study of Anti-telomerase T CD4 Immunity in Melanoma(LyTéloMel) | unknown | N/A | 200 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jul 20, 2016 | clinicaltrials |
| NCT02105168 | Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment(MSN) | unknown | N/A | 2,200 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jun 10, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Jun 14, 2019source: clinicaltrials